glp 1 in non diabetic GLP-1 use tripled among non-diabetics, reaching $5.8B 2022 Activation of the GLP-1 receptor

The findings concerning human gut microbiota remain controversial

6 Similarly, as GLP-1RAs significantly reduced the risk of MACE, mortality from CV causes, when compared with placebo, ADA has suggested that these medications should be used in patients with underlying cardiovascular disease

Unmet needs for better A1C control and additional weight loss still exist, but the bar is continuously being raised

top of page Tirzepatide Tirzapatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)

Well go over the basics of what to look for in a sharps container, where to get one, how to use it, and how to properly dispose of it once its full